Venöse Thrombembolien bei Tumorpatienten

 

 Buy Article Permissions and Reprints

Summary

Venous thrombembolism (VTE) is one of the most frequent complication in cancer patients. The current options in prophylaxis and therapy have to be balanced against the risks of major bleeding and the burden for the patients. The Gesellschaft für Thrombose- und Hämostaseforschung, the Deutsche Gesellschaft für Palliativmedizin and the German speaking Societies of Hematology and Oncology have recently published guidelines on VTE in cancer patients. Recommendations include diagnostics, individual prophylaxis and treatment.

Zusammenfassung

Venöse Thrombembolien (VTE) gehören zu den häufigen Komplikationen bei Tumorpatienten und sind ein prognostisch ungünstiges Zeichen. Die aktuellen und effizienten Möglichkeiten der medikamentösen Prophylaxe und Therapie sind abzuwägen gegen das Blutungsrisiko und die Belastungen für den Patienten. Gemeinsam mit der Gesellschaft für Thrombose- und Hämostaseforschung und der Deutschen Gesellschaft für Palliativmedizin haben die deutschsprachigen Fachgesellschaften der Hämatologie und Onkologie kurzgefasste Leitlinien erarbeitet. Schwerpunkte sind die rationelle Diagnostik, Indikationen zur Prophylaxe in Abhängigkeit von den individuellen Risikofaktoren und die Differenzialtherapie.

^* Onkopedia ist ein Kooperationsprojekt von DGHO Deutsche Gesellschaft für Hämatologie und Onkologie, OeGHO Österreichische Gesellschaft und SGH+SSH.

• Literatur

• 1 Ay C, Pabinger I. Test predictive of thrombosis in cancer. Thromb Res 2010; 125 (Suppl. 02) S12-S15.
  CrossrefPubMedGoogle Scholar
• 2 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thrombembolism in cancer patients. Blood 2010; 116: 5377-5372.
  CrossrefPubMedGoogle Scholar
• 3 Carrier M, Le Gal G, Wells PS. et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism. Ann Int Med 2008; 140: 323-333.
  CrossrefPubMedGoogle Scholar
• 4 Carrier M, Le Gal G, Tay J. et al. Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide and lenalidomide: a systematic review and meta-analysis. Meeting of the American Society of Hematology. Abstract 1090, 2010
  PubMedGoogle Scholar
• 5 Connolly GC, Khorana AK. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl. 02) S1-S7.
  CrossrefPubMedGoogle Scholar
• 6 Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848-4857.
  CrossrefPubMedGoogle Scholar
• 7 Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 20010; 363: 2559-2561.
  CrossrefPubMedGoogle Scholar
• 8 Kakkar AK. Prevention of venous thromboembolism in the cancer surgical patient. J Clin Oncol 2009; 29: 2881-4884.
  PubMedGoogle Scholar
• 9 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 454S-545S.
  CrossrefPubMedGoogle Scholar
• 10 Khorana AA, Connolly GC. Assessing risk for venous thromboembolism in the patients with cancer. J Clin Oncol 2009; 27: 4839-4847.
  CrossrefPubMedGoogle Scholar
• 11 Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27: 4895-4901.
  CrossrefPubMedGoogle Scholar
• 12 Le Gal G, Righini M, Roy PM. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171.
  CrossrefPubMedGoogle Scholar
• 13 Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
  CrossrefPubMedGoogle Scholar
• 14 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
  CrossrefPubMedGoogle Scholar
• 15 Mandala M, Labianca R. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res 2010; 125 (Suppl. 02) S117-S119.
  CrossrefPubMedGoogle Scholar
• 16 Palumbo A, Rajkumar SV, Dimopoulos MA. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
  CrossrefPubMedGoogle Scholar
• 17 Perry JR, Julian JA, Laperriere NJ. et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 08: 1959-1965.
  CrossrefPubMedGoogle Scholar
• 18 Piccioli A, Lensing AW, Prins MH. et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 02: 884-889.
  CrossrefPubMedGoogle Scholar
• 19 Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 29: 4885-4888.
  CrossrefPubMedGoogle Scholar
• 20 Riess H, Pelzer U, Opitz M. et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J Clin Oncol. 2010 28. (Suppl): Abstract 4033.
  PubMedGoogle Scholar
• 21 S2-Leitlinie zur Diagnostik und Therapie der Venenthrombose und der Lungenembolie in Deutschland 2010. http://www.awmf.org/leitlinien/detail/ ll/065-002.html
  PubMedGoogle Scholar
• 22 Shivakumar SP, Anderson DR, Couban S. Catheterassociated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-4864.
  CrossrefPubMedGoogle Scholar
• 23 Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133.
  CrossrefPubMedGoogle Scholar
• 24 Tran QNH. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palli Med 2010; 27: 416-419.
  CrossrefPubMedGoogle Scholar
• 25 Wells PS, Hirsh J, Anderson DR. et al. Accuracy of clinical assessment of deep vein thrombosis. Lancet 1995; 345: 1326-1330.
  CrossrefPubMedGoogle Scholar
• 26 Wells PS, Ginsberg JS, Anderson DR. et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.
  CrossrefPubMedGoogle Scholar